S1P receptor

Assets acting on this target.

Class
S1P receptor modulator
Pathway
Lymphocyte egress (S1P1/S1P5)

The sphingosine-1-phosphate (S1P) receptor family comprises five G-protein-coupled receptor subtypes (S1P1 through S1P5) that respond to the bioactive lipid S1P. S1P1 in particular controls the exit of lymphocytes (white blood cells involved in immune surveillance and autoimmune attack) from lymph nodes into the bloodstream. Small molecules that modulate S1P receptors bind S1P1 (and, depending on the compound, additional subtypes such as S1P4 or S1P5) and cause the receptor to be internalized and degraded within lymphocytes, trapping these cells inside lymph nodes rather than blocking their function outright. This reduces the number of circulating lymphocytes able to reach sites of inflammation, which is useful in autoimmune and inflammatory diseases such as multiple sclerosis and inflammatory bowel disease, where self-reactive lymphocytes drive tissue damage. Because the effect is a reversible redistribution of cells rather than their destruction, immune competence can recover once treatment stops. Different agents in this class vary in how many S1P receptor subtypes they engage; broader or narrower selectivity influences both the intended immunological effect and effects on other organ systems where S1P receptors are expressed, such as the heart and vasculature. This mechanism represents an oral, targeted alternative to biologic immunosuppressants for chronic autoimmune conditions.

By indication

S1P receptor drugs compared

8 drugs, stage by indication
8 drugs acting on S1P receptor: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
etrasimodVelsipityEverest Medicines (Beijing) Co., Ltd., PfizerSmall molecule (S1P1,4,5 modulator)ApprovedApproved in Ulcerative Colitis
fingolimod (Gilenya)GilenyaNovartis, Tanabe Pharma Corporationsmall moleculeApprovedApproved in Multiple Sclerosis
ozanimodZeposiaBristol-Myers SquibbSmall molecule (S1P1,5 modulator)ApprovedApproved in Multiple Sclerosis; Approved in Ulcerative Colitis
PonesimodLaboratoires Juvisé Pharmaceuticals, Vanda Pharmaceuticalssmall moleculeApprovedApproved in Multiple Sclerosis; Phase 3 in Psoriasis; Phase 3 in Ulcerative Colitis
Siponimod (Mayzent)MayzentNovartissmall moleculeApprovedApproved in Multiple Sclerosis
Tascenso ODTCycle Pharmaceuticals Ltd., Handa Neuroscience, LLCsmall moleculeApprovedApproved in Multiple Sclerosis
amiselimodBausch Health, Tanabe Pharma CorporationSmall molecule (oral S1P receptor modulator)Phase 2Phase 2 in Crohn's Disease; Phase 2 in Ulcerative Colitis
tamuzimodEli LillySmall molecule (oral S1P1 receptor modulator)Phase 2Phase 2 in Ulcerative Colitis

← all mechanisms